3 groups based on receipt of cardiac catheterization (cath) < 12 hours of lytics (early cath,N=261), > 12h after lytics (late cath,N=451) or no cath (conservative treatment,N=1056). The likelihood of in-hospital mortality and reinfarction was determined using multivariate analysis. Results: 41% pts underwent cath during index hospitalization. 89% of eady cath pts had a PCI (pemutaneous coronary intervention) as opposed to 61% of the late cath group (p < 0.0001). The outcomes of the early cath group did not differ significantly from the lyrics only group. However, the incidence of in-hospital death was significantly lower in the late cath group as compared to the lytics only group (2% Versus 6.8%, p 0.0002). This remained true even after controlling for differences in baseline and in-hospital character° istics between the 2 groups (late oath mortality OR 0.3, 95%CI 0.13-0.63). The likelihood of a reinfarction was, however, significantly high in the late cath group. Conclusions: Although lytics substantially reduce mortality after an acute STE MI many pts may derive an additional benefit from the use of a cardiac cath and, if indicated, a PCI, especially if performed non-urgently. 
Odds of death and reinfarction during

Background & Methods:
Higher white blood cell counts (WBCC) have been associated with higher mortality in the setting of acute coronary syndromes (ACS). We sought to examine if this relationship was true independent of other cardiac markers of inflammation and/or infarction in TACTICS -TIM118.
Results:
The median WBCC (103/ram 3) at baseline was 8.1 [interquartile range (IR) 6.7-10.1]. Median WBCC was higher in patients who died by 30 days (9.1, IR 7.8-12 vs. 8.1, IR 6.6-10.1; p=0.0016) and 180 days (8.75, IR 7.6-10.95 vs. 8.1, IR 6.6-10.1; p=0.0047).
Of the 1841 patients with WBCC & C-reactive protein (CRP) data, patients with a low WBCC (<25 th percentile) and a low CRP (<1.5 mg/dL) had a 6-month mortality rate of 0,7%, those with a low CRP but a high WBCC had a rate of 2.8%, and those with a high CRP regardless of WBCC had a mortality rate of 6.2% (p<0.0001, Z 2 for trend). In a Cox proportional hazards model adjusted for age, smoking, craatinine, prior MI, prior aspirin use, troponin level, and ST deviation, patients with low CRP but high WBCC remained at significantly higher risk of death at 180 days [hazard ratio (HR) 5.4, p=0.02], and patients with high CRP were at even higher risk (HR 12.2, p=0.0007).
Conclusion:
Higher baseline WBCC are associated with a higher risk of 6-month mortal- Background: Coronary lesions of patients with acute coronary syndromes are characterized by intense inflammation. The MIRACL trial showed that atorvastatin 80 mg/day reduced recurrent ischemic events in the first 16 weeks. The purpose of this study was to determine whether intensive lipid lowering can reduce serum C-reactive protein (CRP), a marker of inflammation, in patients with unstable angina or non-Q-wave MI. Methods:
Blood samples were collected at baseline and at 16 weeks from 2,322 of 3,086 patients participating in the MIRACL trial. C-reactive protein (CRP) was measured by a highly sensitive immunoassay. The change in CRP was compared between patients randomly assigned to atorvastatin vs. placebo. The change in CRP was also evaluated separately in patients with unstable angina and non-Q-wave myocardial infarction. Results: The baseline median CRP was similar in the patients assigned to atorvastatin (10.0 mg/L) and placebo (9.9 mg/L), (p=NS). The reduction in CRP over 16 weeks of treatment was significantly greater in patients on atorvastatin (-7.5 mg/L) compared to placebo (-6.0 mg/ L, p<0.001). Atorvastatin led to a greater reduction in CRP in patients with non-Q-wave MI (-15.9 vs -10.0 mg/L, atorvastatin vs. placebo, p=0.011), as well as in patients with the unstable angina (-3.5 vs -2.5 rag/L, atorvastatin vs. placebo, p=0.003). Conclusion:
Atorvastatin (80mg/day) reduced CRP, a marker of inflammation, in patients with acute coronary syndromes. This was observed in patients with non-Q-wave MI as well as unstable angina. Thus, in patients with acute coronary syndromes, atorvastatin reduces inflammation, a mechanism associated with plaque stabilization. This effect may contribute to the clinical benefit observed in the MIRACL trial.
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